Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.49 |
| ▸ | RAF1 | P04049 | 6/20 | 0.49 |
| ▸ | LCK | P06239 | 4/20 | 0.47 |
| ▸ | FYN | P06241 | 4/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.47 |
| ▸ | KIT | P10721 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 4/20 | 0.47 |
| ▸ | FLT4 | P35916 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430237 | 0.84 | BRAF (0.49) | BRAFRAF1LCKFYNPDGFRB | |
| SCHEMBL5431873 | 0.81 | BRAF (0.46) | BRAFRAF1LCKFYNPDGFRB | |
| SCHEMBL5424304 | 0.81 | RAF1 (0.52) | BRAFRAF1LCKFYNPDGFRB | |
| SCHEMBL3546037 | 0.79 | RAF1 (0.47) | BRAFRAF1LCKFYNPDGFRB | |
| SCHEMBL3540218 | 0.79 | BRAF (0.46) | BRAFRAF1LCKFYNPDGFRB | |
| SCHEMBL545887 | 0.78 | KDR (0.51) | BRAFRAF1LCKFYNPDGFRB | |
| SCHEMBL3544963 | 0.78 | TRPV1 (0.48) | BRAFRAF1 | |
| SCHEMBL3544956 | 0.78 | TRPV1 (0.48) | BRAFRAF1 | |
| SCHEMBL544984 | 0.77 | BRAF (0.43) | BRAFRAF1LCKFYNPDGFRB | |
| SCHEMBL3547764 | 0.77 | RAF1 (0.42) | BRAFRAF1LCKFYNPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | BRAF 215/4885RAF1 198/4885LCK 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.